Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rhythm Pharmaceuticals reports robust Q4 performance and eyes growth

Rhythm Pharmaceuticals had a strong performance in Q4 2022, driven by increased IMCIVREE sales and strategic pipeline expansions.
While facing challenges in logistics and reimbursement, the company's strengths lie in its geographic expansion, pipeline diversification, and patient-focused approach.
Opportunities for growth include upcoming launches, patient identification efforts, and maximizing the potential of the BBS commercial opportunity.

Rhythm Pharmaceuticals excels in Q1 with IMCIVREE revenue surge

Rhythm Pharmaceuticals demonstrated strong financial performance and market acceptance of IMCIVREE, supported by robust revenue growth and cash reserves.
While facing challenges in pricing negotiations and patient transitions, the company is well-positioned to capitalize on opportunities for further growth and development.
The identification of key genes in the DAYBREAK trial and positive patient feedback highlight the company's commitment to innovation and patient-centric care.
Overall, Rhythm Pharmaceuticals' Q1 earnings call showcases a promising outlook with solid performance, strategic strengths, addressable challenges, and growth opportunities.

Rhythm Pharmaceuticals excels in Q2, eyes international growth opportunities

Rhythm Pharmaceuticals delivered a strong Q2 performance with notable achievements in commercial execution and clinical development. Despite challenges in market ramp-up and reimbursement delays, the company remains well-capitalized and focused on strategic priorities. Opportunities for growth through international expansion and new drug formulations position Rhythm for continued success.

Rhythm Pharmaceuticals excels in Q3, faces discontinuation challenges

Rhythm Pharmaceuticals is making significant progress in commercial expansion and clinical trials, supported by strong financial position. Challenges include administrative hurdles and managing discontinuation rates. Opportunities exist in expanding prescriber base, educating specialties, and advancing clinical trials for younger patients.

Rhythm Pharmaceuticals surpasses revenue expectations, eyes international expansion and patient-centric innovation

Rhythm Pharmaceuticals delivered strong financial performance, highlighted by solid commercial execution and international market successes, despite challenges with Medicaid coverage.
The company's focus on innovation, unique value propositions, and upcoming milestone achievements position it for continued growth and market leadership.
Addressing discontinuation rates, Medicaid issues, and maximizing opportunities in international markets are key priorities for Rhythm Pharmaceuticals to drive sustained success.

Rhythm Pharmaceuticals reports strong Q1 performance and international growth

Rhythm Pharmaceuticals' Q1 performance reflects strong commercial traction, international growth, and strategic advancements in clinical programs.
While facing challenges like Medicaid changes and discontinuations, the company's proactive measures and focus on patient care position it well for growth.
Opportunities in new markets, patient populations, and improved retention strategies offer avenues for future expansion and revenue growth.
Overall, Rhythm Pharmaceuticals' earnings call highlights a balanced outlook with a focus on innovation, patient support, and international expansion.

Rhythm Pharmaceuticals reports robust Q2 revenues, eyes European growth

Rhythm Pharmaceuticals demonstrated solid revenue performance in Q2 2024 driven by IMCIVREE sales
The company maintains a strong cash position and is progressing well with its pipeline development
Challenges include managing expenses to ensure profitability and sustaining operations until 2026
Opportunities lie in product expansion, successful trial outcomes, and operational optimization

Rhythm Pharmaceuticals excels in Q3 with revenue growth and clinical progress

Rhythm Pharmaceuticals demonstrated strong performance in Q3 2024 with revenue growth and positive clinical trial outcomes.
The company's focus on expansion, engagement, and milestone achievements positions it well for future growth and market penetration.
While facing challenges in managing expenses and addressing analyst inquiries, Rhythm Pharmaceuticals has opportunities for international expansion and therapeutic advancements.
Overall, Rhythm Pharmaceuticals' strategic approach and financial stability indicate a promising outlook for continued success and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 3:00 p.m. ET.

Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

- Interview-based research published in Advances in Therapy demonstrates setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food –

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

SVB Financial Group

Axsome Therapeutics

Vir Biotechnology

The collapse of SVB will leave early-stage biotech companies in a funding dearth. But big-name biotech stocks will emerge largely untouched.

Biotech Stocks And The SVB Collapse — Here's What We Know

The collapse of Silicon Valley Bank will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should escape unscathed.

SVB fall casts shadow on early-stage U.S. biotech

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Derek Archila - Wells Fargo Securities Corinne Jenkins - Goldman Sachs Dae Gon Ha - Stifel Whitney Ijem - Canaccord Genuity Michael Higgins - Ladenburg Joseph Stringer - Needham & Company Michael Riad - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call.

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2022 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 8.54% and 24.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

-- IMCIVREE ® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval -- -- IMCIVREE now available in eight ex-U.S. markets; first commercial sales for BBS expected in Germany in 2Q 2023 --

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

- Rare disease company in preclinical development for congenital hyperinsulinism -

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 1, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide -

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

Belite Bio Inc

Transmedics Group Inc

These three have had big-time share gains backed up by breakthrough science.

3 Breakout Growth Stocks to Buy for the Long Haul

Rhythm Pharmaceuticals is planning to get approvals for setmelanotide in an incremental fashion. Each new approval in a rare disease will add to the topline.

Rhythm Pharma: An Incremental Approach Works Well For Setmelanotide

-- Health Canada accepts for review new drug submission for setmelanotide for the treatment of obesity and control of hunger in BBS and biallelic POMC, PCSK1 and LEPR deficiencies -- BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that Great Britain's Medicines & Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age and older.

Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Dae Gon - Stifel Corinne Jenkins - Goldman Sachs Joseph Stringer - Needham & Company Michael Higgins - Ladenburg Operator Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter 2022 Earnings Conference Call.

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2022 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 21.78% and 20.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates

-- Previously disclosed data demonstrated statistically significant and clinically meaningful reductions in weight and hunger in patients with Bardet-Biedl syndrome -- BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that previously disclosed results from a Phase 3 clinical trial that evaluated IMCIVREE® (setmelanotide), an MC4R agonist, in patients with Bardet-Biedl syndrome (BBS) have been published in the peer-reviewed journal The Lancet Diabetes and Endocrinology. The trial met its primary endpoint and all key secondary endpoints, with statistically significant reductions in weight and hunger at 52 weeks on therapy.

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

-- U.S. launch of IMCIVREE ® (setmelanotide) for Bardet-Biedl Syndrome progresses with strong demand with more than 120 prescriptions since FDA approval -- -- EC authorization for IMCIVREE expanded to include BBS; UK launch in POMC and LEPR deficiencies underway --

Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update

-- Analyses of Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) in children with BBS showed a significant positive correlation between degree of hyperphagia and body mass index (BMI) -- -- 84% of patients with BBS in Phase 3 clinical trial showed clinical benefit of improvement in one measure or more of weight, hunger, or QoL following setmelanotide treatment --

Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society's Annual Meeting at ObesityWeek®

-- Phase 3 clinical trial design reflects feedback obtained during recent discussions with FDA -- -- 89 percent (16 of 18) patients achieved primary endpoint with a BMI decrease greater than 5 percent at 16 weeks on setmelanotide therapy (P

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline

Akero Therapeutics Inc

Astria Therapeutics

HeartBeam

ContraFect

Humanigen

Otonomy

Vigil Neuroscience

Virios Therapeutics

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

Amgen

Biogen

bluebird bio

Chemocentryx

Forma Therapeutics Holdings

iShares Nasdaq Biotechnology ETF

Karuna Therapeutics Inc

Novo Nordisk

Pfizer

SPDR S&P Biotech ETF

Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach.

Biotech Stocks Well-Positioned For Fourth Quarter

Today, we circle back on Rhythm Therapeutics for the first time in over a year and a half. The company continues to advance its main asset Imcivree across multiple indications and recently addressed its near-term financing needs.

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management.

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

-- Book developed in collaboration with the Bardet-Biedl Syndrome Foundation -- -- BBS Global Day on Sept. 24 coordinated by BBS International --

News for Rhythm Pharmaceuticals Stock (RYTM)